A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
about
Minireview: Regulatory T Cells and Ovarian Cancer.MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trialThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Past, present and future targets for immunotherapy in ovarian cancerUric acid enhances the antitumor immunity of dendritic cell-based vaccineNanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancerThe Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.Ovarian cancer and the immune system.Potential approaches for more successful dendritic cell-based immunotherapy.Cellular immunotherapy of cancer: an overview and future directions.Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.Understanding dendritic cell immunotherapy in ovarian cancer.Immune modulation by dendritic-cell-based cancer vaccines.Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.Immunotherapy for ovarian cancer: what are the targets of the future?Mechanisms regulating T-cell infiltration and activity in solid tumors.Role of tumor microenvironment in ovarian cancer pathobiology.Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunitiesTargeting the Microenvironment in High Grade Serous Ovarian CancerA randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
P2860
Q30244214-9DFF1393-7E90-468B-B64D-FC58C1C049BDQ33614005-26C6DE54-0796-45DA-9256-277EDCB4F37EQ33815087-F047AC4E-2E18-44ED-AC6B-E666817B5B31Q34658452-A2166AFE-B55D-4F71-A2F4-E8E7A09693B2Q35034010-D0EFB259-CCE7-4601-888F-AD519918CD2EQ36265772-A1A48EAC-E486-40C8-BBEE-8DF1258ECEC4Q36269694-CCFA8E46-5D07-4B34-B485-01AE9E898C92Q37022497-A0604978-CBEE-4390-9AD6-3F213D8B0691Q37180279-A737D758-217A-45AC-A7C0-7F1937577FEDQ37594784-BD7AEC1F-41DF-43D3-9E34-47F9EF9A38C6Q38305650-C4E2A965-A6F7-40AD-9413-C4BB8C4FD666Q38673161-71A5ECB1-8E0B-4CD4-9DA3-B17F9BFD312BQ38788212-6D1FD5D9-AC72-43A6-9C48-AF44E3783562Q38808249-691A434B-7D89-4C20-A410-7B339FE136C0Q39147683-814C6B99-8720-4A26-AD94-4EB835E061C1Q41205250-176A6CEF-DECC-4006-A815-2C48471E5FF0Q42695076-F1738CE5-09C3-4B90-9BD2-6F453C4C19B1Q48489326-021AA9FC-4AEA-434A-BAC2-890B0155D770Q50089395-BF554028-F034-4D23-8F13-C4CBA4582D6CQ55078149-0CCB8205-D9A8-4577-8FB6-531030704B67Q58724750-E065F631-E898-4EDC-A84C-EE75233434B0Q58789499-0E4F82B1-431B-4B9E-ADD6-70E39A303BA3Q58795622-3959FCFD-0EB1-41D8-802D-FBC89D70CF31
P2860
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A Phase I vaccine trial using ...... for recurrent ovarian cancer.
@en
type
label
A Phase I vaccine trial using ...... for recurrent ovarian cancer.
@en
prefLabel
A Phase I vaccine trial using ...... for recurrent ovarian cancer.
@en
P2093
P2860
P356
P1476
A Phase I vaccine trial using ...... e for recurrent ovarian cancer
@en
P2093
Cheryl L Chiang
Janos Tanyi
Klara Balint
Lana E Kandalaft
Rosemarie Mick
P2860
P2888
P356
10.1186/1479-5876-11-149
P577
2013-06-18T00:00:00Z